Payment overview · 2025
General Payments
$2,035.33
83 reported records · 37 companies
Healthcare provider profile · identity verified
Rita Gupta, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · CLINTON, MD · NPI 1003857269
Verified facts
What the public records show
CMS Open Payments records show Rita Gupta, M.D. received $2,035.33 in general payments during 2025 across 83 reported records.
Janssen Biotech, Inc. accounted for 11.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 63 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jakafi, Tukysa, Verzenio.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUKYSA as an associated drug or biological on 5271 records involving 2869 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tukysa by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRYCEL as an associated drug or biological on 32 records involving 32 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Sprycel by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Verzenio by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUKYSA as an associated drug or biological on 10028 records involving 4442 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tukysa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $226.87 | 11.2% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $220.59 | 10.8% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $173.80 | 8.5% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $151.27 | 7.4% | 8 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $126.17 | 6.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $109.57 | 5.4% | 4 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $91.96 | 4.5% | 3 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $65.78 | 3.2% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $64.19 | 3.1% | 2 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $55.04 | 2.7% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $52.66 | 2.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $48.54 | 2.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.89 | 2.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.32 | 2.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.16 | 2.1% | 2 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.49 | 2.0% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $36.20 | 1.8% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $30.94 | 1.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $29.28 | 1.4% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $29.26 | 1.4% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.07 | 1.4% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $27.93 | 1.4% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $27.34 | 1.3% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.08 | 1.3% | 1 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $24.89 | 1.2% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.29 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.81 | 1.1% | 1 | 2025 |
| ACCORD HEALTHCARE, INC. | Unresolved — no canonical attribution shown | $21.26 | 1.0% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $19.65 | 1.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.08 | 0.9% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $16.78 | 0.8% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $16.65 | 0.8% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.58 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.48 | 0.8% | 1 | 2025 |
| Acrotech Biopharma Inc. | Unresolved — no canonical attribution shown | $16.23 | 0.8% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $13.70 | 0.7% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $13.53 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,940.33 | 82 |
| Education | $95.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $173.80 | 8 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $164.00 | 5 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $164.00 | 5 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $136.59 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $102.36 | 3 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $102.36 | 3 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $87.45 | 3 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $77.53 | 3 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $74.60 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $73.69 | 3 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $67.10 | 2 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $65.78 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $64.19 | 2 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $63.76 | 2 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $55.04 | 2 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $52.66 | 2 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $52.09 | 2 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $49.42 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $48.54 | 2 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $46.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $46.89 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $44.58 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $41.49 | 4 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $40.49 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $31.42 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $30.94 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| Somatuline Depot Normalized: somatuline depot |
Drug | Ipsen Biopharmaceuticals, Inc | $29.26 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $27.93 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $27.34 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $26.27 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $26.08 | 1 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| TGCT Normalized: tgct |
Drug | Deciphera Pharmaceuticals Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| Phyrago Normalized: phyrago |
Drug | Cycle Pharmaceuticals Inc | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Camcevi Normalized: camcevi |
Drug | ACCORD HEALTHCARE, INC. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Incyte Corporation | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| BELEODAQ Normalized: beleodaq |
Drug | Acrotech Biopharma Inc. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TUKYSA tukysa |
2025 | Tukysa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | TUKYSA open payments reported associated product |
CMS Open Payments — General Payments 5271 supporting records · 2869 recipient NPIs · example record 1228794645 |
Tukysa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | SPRYCEL open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 32 recipient NPIs · example record 1184390211 |
Sprycel · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | TUKYSA open payments reported associated product |
CMS Open Payments — General Payments 10028 supporting records · 4442 recipient NPIs · example record 1228794329 |
Tukysa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 245 | 71 |
| Letrozole | Letrozole | 157 | 40 |
| Eliquis | Apixaban | 134 | 33 |
| Exemestane | Exemestane | 72 | 17 |
| Warfarin Sodium | Warfarin Sodium | 57 | 13 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Hydroxyurea | Hydroxyurea | 29 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 24 | suppressed |
| Revlimid | Lenalidomide | 20 | suppressed |
| Lenalidomide | Lenalidomide | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | 13 |
| Folic Acid | Folic Acid | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Sprycel | Dasatinib | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Verzenio | Abemaciclib | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Gabapentin | Gabapentin | 12 | suppressed |
| Tukysa | Tucatinib | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,035.33 · 83 records | Janssen Biotech, Inc. | ADCETRIS, BELEODAQ, BESREMI, BOSULIF, BRAFTOVI, BRUKINSA, CABOMETYX, CARVYKTI, Camcevi, DARZALEX, Doptelet, ELIQUIS, ELREXFIO, ENHERTU, Epkinly, FOTIVDA, Fabhalta, GIVLAARI, IBRANCE, IMBRUVICA, Itovebi, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LORBRENA, LYNPARZA, Lenvima, MEKTOVI, MI CANCER SEEK, NERLYNX, NIKTIMVO, ORGOVYX, Onivyde, Optune Lua (NovoTTF-200T), Orserdu, PADCEV, PLUVICTO, Phyrago, Polivy, QINLOCK, ROMVIMZA, RYTELO, SCEMBLIX, Somatuline Depot, TALVEY, TALZENNA, TECVAYLI, TEVIMBRA, TGCT, TUKYSA, Trodelvy, ULTOMIRIS, VENCLEXTA, VERZENIO, Vonjo, Vyloy, WELIREG, XTANDI, ZEJULA, ZYNLONTA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ARRAY BIOPHARMA INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error